Infliximab accelerates wound healing in diabetic mice by aggravating macrophage polarization

Delayed wound healing is one vital complication of diabetes mellitus (DM) that adversely impacts patient quality of life. Infliximab (INF), a monoclonal tumor necrosis factor α (TNF-α) antibody, has been investigated for its therapeutic potential across various diseases through displaying anti-inflammation ability. However, the regulatory mechanisms by which INF influences and correlates with delayed wound healing in DM remain unclear. In this study, we first induced diabetes in mice using streptozotocin (STZ) to establish a DM model, and then excision wounds were generated. We observed that wound closure was significantly retarded in DM mice, but this effect was reversed following INF treatment (5 mg/kg). Moreover, INF treatment attenuated the heightened inflammation observed in DM mice. Furthermore, we found that INF expedited the M2 phenotype polarization in DM mice. Mechanistically, INF was shown to delay activation of the nuclear factor kappa-B (NF-κB) pathway. To sum up, our findings demonstrate that in diabetic mice, INF facilitates wound healing by modulating macrophage polarization, and refrained the NF-κB pathway, supporting INF as a promising treatment approach for improving wound healing in diabetics.

Infliximab; Wound healing; Macrophage polarization; Diabetes mellitus; NF-κB pathway

[1] Wang PH, Huang BS, Horng HC, Yeh CC, Chen YJ. Wound healing. Journal of the Chinese Medical Association. 2018; 81: 94–101.

[2] Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA. 2023; 330: 62–75.

[3] Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. Translational Research. 2021; 236: 109–116.

[4] Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. Journal of Clinical Investigation. 2007; 117: 1219–1222.

[5] Salazar JJ, Ennis WJ, Koh TJ. Diabetes medications: impact on inflammation and wound healing. Journal of Diabetes and Its Complications. 2016; 30: 746–752.

[6] Ansurudeen I, Sunkari VG, Grünler J, Peters V, Schmitt CP, Catrina SB, et al. Carnosine enhances diabetic wound healing in the db/db mouse model of type 2 diabetes. Amino Acids. 2012; 43: 127–134.

[7] Sommer K, Jakob H, Reiche C, Henrich D, Sterz J, Frank J, et al. 11,12 Epoxyeicosatrienoic acid rescues deteriorated wound healing in diabetes. International Journal of Molecular Sciences. 2021; 22: 11664.

[8] Borges PA, Waclawiak I, Georgii JL, Fraga-Junior VDS, Barros JF, Lemos FS, et al. Adenosine diphosphate improves wound healing in diabetic mice through P2Y12 receptor activation. Frontiers in Immunology. 2021; 12: 651740.

[9] Peddibhotla S, Caples K, Mehta A, Chen QY, Hu J, Idlett-Ali S, et al. Triazolothiadiazine derivative positively modulates CXCR4 signaling and improves diabetic wound healing. Biochemical Pharmacology. 2023; 216: 115764.

[10] Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opinion on Investigational Drugs. 2006; 15: 181–184.

[11] Poutoglidou F, Pourzitaki C, Manthou ME, Samoladas E, Saitis A, Malliou F, et al. Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model. Inflammopharmacology. 2021; 29: 661–672.

[12] Yang T, Hu SL, Li L, Wang Y, Jiang T. Effects of infliximab on oxidative stress and inflammation of H9c2 cells induced by H2O2. Molecular and Cellular Biology. 2023; 69: 213–218.

[13] Zhou Y, Fan R, Botchway BOA, Zhang Y, Liu X. Infliximab can improve traumatic brain injury by suppressing the tumor necrosis factor alpha pathway. Molecular Neurobiology. 2021; 58: 2803–2811.

[14] Dadsetan S, Balzano T, Forteza J, Agusti A, Cabrera-Pastor A, Taoro-Gonzalez L, et al. Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy. Journal of Neuroinflammation. 2016; 13: 245.

[15] Sharifiaghdam M, Shaabani E, Faridi-Majidi R, De Smedt SC, Braeckmans K, Fraire JC. Macrophages as a therapeutic target to promote diabetic wound healing. Molecular Therapy. 2022; 30: 2891–2908.

[16] Willenborg S, Injarabian L, Eming SA. Role of macrophages in wound healing. Cold Spring Harbor Perspectives in Biology. 2022; 14: a041216.

[17] Klabukov I, Shestakova V, Krasilnikova O, Smirnova A, Abramova O, Baranovskii D, et al. Refinement of animal experiments: replacing traumatic methods of laboratory animal marking with non-invasive alternatives. Animals. 2023; 13: 3452.

[18] Zhao L, Wu Q, Long Y, Qu Q, Qi F, Liu L, et al. microRNAs: critical targets for treating rheumatoid arthritis angiogenesis. Journal of Drug Targeting. 2024; 32: 1–20.

[19] Ban E, Jeong S, Park M, Kwon H, Park J, Song EJ, et al. Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity. Biomedicine & Pharmacotherapy. 2020; 121: 109613.

[20] Han DH, Kim WK, Lee C, Park S, Lee K, Jang SJ, et al. Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice. Scientific Reports. 2022; 12: 9640.

[21] Han X, Tao Y, Deng Y, Yu J, Sun Y, Jiang G. Metformin accelerates wound healing in type 2 diabetic db/db mice. Molecular Medicine Reports. 2017; 16: 8691–8698.

[22] Guan Y, Niu H, Liu Z, Dang Y, Shen J, Zayed M, et al. Sustained oxygenation accelerates diabetic wound healing by promoting epithelialization and angiogenesis and decreasing inflammation. Science Advances. 2021; 7: eabj0153.

[23] Leal EC, Carvalho E, Tellechea A, Kafanas A, Tecilazich F, Kearney C, et al. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. The American Journal of Pathology. 2015; 185: 1638–1648.

[24] Li S, Ding X, Yan X, Qian J, Tan Q. ceAF ameliorates diabetic wound healing by alleviating inflammation and oxidative stress via TLR4/NF-κB and Nrf2 pathways. Journal of Diabetes Research. 2023; 2023: 2422303.

[25] Moura J, Sørensen A, Leal EC, Svendsen R, Carvalho L, Willemoes RJ, et al. microRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammation. Scientific Reports. 2019; 9: 5836.

[26] Hemperly A, Vande Casteele N. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clinical Pharmacokinetics. 2018; 57: 929–942.

[27] Zhou X, Ye C, Jiang L, Zhu X, Zhou F, Xia M, et al. The bone mesenchymal stem cell-derived exosomal miR-146a-5p promotes diabetic wound healing in mice via macrophage M1/M2 polarization. Molecular and Cellular Endocrinology. 2024; 579: 112089.

[28] Li S, Ding X, Zhang H, Ding Y, Tan Q. IL-25 improves diabetic wound healing through stimulating M2 macrophage polarization and fibroblast activation. International Immunopharmacology. 2022; 106: 108605.

[29] Ding Y, Yang P, Li S, Zhang H, Ding X, Tan Q. Resveratrol accelerates wound healing by inducing M2 macrophage polarisation in diabetic mice. Pharmaceutical Biology. 2022; 60: 2328–2337.

[30] Xing N, Yang J, Wang H, Peng L, Liu X, Chen J, et al. Stromal vascular fraction gel promoted wound healing and peripheral nerve repair in diabetic rats via TLRs/MyD88/NF-κB signaling pathway. Journal of Biomaterials Applications. 2023; 38: 146–156.

[31] Zhen Z, Wei S, Yunfei W, Jie X, Jienan X, Yiting S, et al. Astragalus polysaccharide improves diabetic ulcers by promoting M2-polarization of macrophages to reduce excessive inflammation via the β-catenin/NF-κB axis at the late phase of wound-healing. Heliyon. 2024; 10: e24644.

[32] Ebaid H, Abdel-Salam B, Hassan I, Al-Tamimi J, Metwalli A, Alhazza I. Camel milk peptide improves wound healing in diabetic rats by orchestrating the redox status and immune response. Lipids in Health and Disease. 2015; 14: 132.

[33] Shinde A, Tang X, Singh R, Brindley DN. Infliximab, a monoclonal antibody against TNF-α, inhibits NF-κB activation, autotaxin expression and breast cancer metastasis to lungs. Cancers. 2023; 16: 52.

[34] Mudgal SK, Kumar S, Gaur R, Singh H, Saikia D, Varshney S, et al. Effectiveness of stem cell therapy for diabetic foot ulcers: a systematic review and GRADE compliant bootstrapped meta-analysis of randomized clinical trials. The International Journal of Lower Extremity Wounds. 2024; 31: 15347346241227530.

[35] Maksimova NV, Michenko AV, Krasilnikova OA, Klabukov ID, Gadaev IY, Krasheninnikov ME, et al. Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period. Bioimpacts. 2022; 12: 51–55.